Factors Predicting Docetaxel-Related Toxicity: Experience at a Single Institution

REFERENCES

• Cortes JF and Pazdur R. Docetaxel. J Clin Oncol 1995; 13: 2643–2655.
   Google Scholar
• Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17: 1413–1424.
   PubMed Web of Science ®Google Scholar
• Sjostrom J, Blomquist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline fail-ure: a randomized phase III study with crossover on progres-sion by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194-1201.
   Google Scholar
• Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456–1466.
   PubMed Web of Science ®Google Scholar
• Chan S, Friedrichs K, Noel D, et al. Prospective ran-domized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341–2354.
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophos-phamide) with FAC (5-fluorouracil, doxorubicin, cyclophos-phamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002; 21: 36a ( Abstr 141).
   Google Scholar
• Fossella FV, De Vore F, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol 2000; 18: 2354–2362.
   PubMed Web of Science ®Google Scholar
• Sheperd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum based chemotherapy. J Clin Oncol 2000; 18: 2095–2103.
   Google Scholar
• Hesketh PJ, Crowley JJ, Burris HA 3rd, et al. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. Cancer J Sci Am 1999; 5: 237–241.
   PubMed Web of Science ®Google Scholar
• Colevas AD, Norris CM, Tishler RB, et al. Phase II trial of docetaxel, cisplatin, fluoruracil and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999; 17: 3503–3511.
   PubMed Web of Science ®Google Scholar
• Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gas-tric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000; 11: 301–306.
   Google Scholar
• Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pan-creatic adenocarcinoma. Eur J Cancer 2000; 36: 1016–1025.
   PubMed Web of Science ®Google Scholar
• Einzig Al, Neuberg D, Remick SC, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13: 87–93, 1996.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Bakoyannis C, Georgoulias V, et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 1999; 10: 1385–1388.
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Gore M, ten Bokkel Huinink W, et al. Docetaxel: an active new drug for treatment of advanced ephitelial ovarian cancer. J Natl Cancer 1995; 87: 676–681.
   PubMed Web of Science ®Google Scholar
• Van Oosterom, Schrijvers D. Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: clinical experience. Anti-Cancer Drugs 1995; 6: 356–368.
   PubMed Web of Science ®Google Scholar
• Burris HA. Optimal use of docetaxel (Taxotere): maximizing its potential. Anti-Cancer Drugs 1996; 7 (Suppl. 2): 25–28.
   PubMed Web of Science ®Google Scholar
• Salminen E, Bergman M, Huhtala S, et al. Docetaxel: standard recommended dose of 100 mg/m2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy. A phase II single-center study. J Clin Oncol 1999; 17: 1127.
   PubMed Web of Science ®Google Scholar
• Clarke SJ, Rivory LP. Clinical pharmacokinetics of doc-etaxel. Clin Pharmacokinet 1999; 36: 99–114.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Burris HA 3rd, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16: 2164–2168.
   Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Welch SR, Raber MN, et al. Comprensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147–159.
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Spielman M, Guastalla JP, et al. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 1999; 35: 1431–1439.
   PubMed Web of Science ®Google Scholar
• Mattson K, Bosquee L, Dabouis G, et al. Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice. Lung Cancer 2000; 29: 205–216.
   PubMed Web of Science ®Google Scholar
• Schutte W, Nagel S, Lautenschlager C, et al. Randomized phase III study of weekly versus three-weekly doc-etaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC). Proceeding Am Soc Clin Oncol 2002; 21: 308a ( Abstr 1228).
   Google Scholar
• Minami H, Sasaki Y, Tahara M, et al. Phase I and pharmacological study of weekly docetaxel in comparison with administration every 3 weeks. Proc Am Soc Clin Oncol 2002; 21: 122a ( Abstr 487).
   Google Scholar
• Hainsworth JD, Burris HA III, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19: 3500–3505.
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Gutschow K, Sommer H, et al. Weekly docetaxel (Taxoteree) in patients with metastatic breast can-cer. Ann Oncol 2001; 12: 1393–1398.
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid reten-tion: final results of a randomized study of the European Organization for Research and Treatment of Cancer, Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15: 3149–3155.
   PubMed Web of Science ®Google Scholar
• Koo LC, Davis ST, Suttle AB, et al. Incidence of chemotherapy-induced alopecia by chemotherapy regimen: a review of published randomized trials. Proc Am Soc Clin Oncol 2002; 21: 264h ( Abstr. 2876).
   Google Scholar
• Hirth, J, Watkins PB, Strawderman M, et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6: 1255-1258.
   Google Scholar
• Goh BC, Lee SC, Wang LZ, et al. Explaining interindi-vidual variability of docetaxel pharmacokinetics and pharmaco-dynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683–3690.
   PubMed Web of Science ®Google Scholar